OTC deficiency is a rare genetic condition and the most prevalent urea cycle disorder. Newborns with neonatal onset OTC deficiency exhibit hyperammonemia symptoms shortly after birth, including ...
When we hear that a person has quirks, we expect to be charmed. But when we hear that a cell-based assay has quirks, we expect to be frustrated. Quirks in cell-based assays tend to complicate drug ...
Avance Biosciences opened its new Potency and Cell-Based Assay Center of Excellence, a purpose-built facility designed to expand and centralize the company’s capabilities in potency and functional ...
SPT Labtech, a global leader in innovative laboratory automation, today announced a strategic collaboration with Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory ...
Boston Cell Standards, Inc. (BCS), a private company bringing modern Quality tools and practices to Clinical Immunohistochemistry (IHC) testing worldwide, announced today that its IHC Reference ...
Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced the launch of Cyto-Cellect® Fc Fusion, a novel assay designed to ...
Funding supports expansion of manufacturing and commercial capacity for SemaCyte microcarrier platform Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory combining ...
CNS-3D Brain Organoids Predict Clinical Seizure Liability Central nervous system (CNS) toxicity accounts for 25% of safety ...
NEW YORK, NY, UNITED STATES, April 27, 2026 /EINPresswire.com/ -- With years of experience in the pharmaceutical and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results